RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort.
J M O'SullivanJ TaylorAaron T GerdsS BuckleyC N HarrisonStephen T OhA F ListKieran HowardH DreauA HamblinAdam J MeadPublished in: Leukemia (2023)
Keyphrases